Drug Trial Radar · NCT01386554
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
Last checked: Nov 20, 2026Latest source record: Nov 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Aug 2011
Primary completion
Nov 21, 2016
Study completion May 5, 2017
Sponsor
- Lead sponsor
- MallinckrodtIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide nephrologists with additional clinical evidence regarding the efficacy and safety of Acthar in subjects with treatment-resistant idiopathic membranous nephropathy. Approximately sixty (60) subjects will be randomized in this double-blind, parallel-group, placebo-controlled, multicenter study comparing Acthar and Placebo administered 2 times per week for a 24-week treatment period followed by a 24-week observation period. The primary objective of this study is to assess the proportion of treatment-resistant subjects (defined as subjects who either have had no response or have suffered a relapse after achieving a partial response to their most recent standard treatment regimen) who have a complete or partial remission of proteinuria in nephrotic syndrome due to idiopathic membranous nephropathy after 24 weeks of treatment.
Conditions
- Proteinuria
- Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin InjectionDrug
Acthar given SC for 6 months
PlaceboDrug
Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API. Placebo given SC for 6 months (80 U two times a week).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 WeeksTime frame: At Visit 8 (Week 24)
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
Mallinckrodt Investigational Site
Sacramento, California
Mallinckrodt Investigational Site
Stanford, California
Mallinckrodt Investigational Site
Jacksonville, Florida
Mallinckrodt Investigational Site
Atlanta, Georgia
Mallinckrodt Investigational Site
Rochester, Minnesota
Mallinckrodt Investigational Site
Reno, Nevada
Mallinckrodt Investigational Site
New York, New York
Mallinckrodt Investigational Site
Chapel Hill, North Carolina
Mallinckrodt Investigational Site
Durham, North Carolina
Mallinckrodt Investigational Site
Bethlehem, Pennsylvania
Mallinckrodt Investigational Site
Charleston, South Carolina
Mallinckrodt Investigational Site
Chattanooga, Tennessee
Mallinckrodt Investigational Site
Houston, Texas
Mallinckrodt Investigational Site
Lubbock, Texas
Mallinckrodt Investigational Site
Toronto, Ontario, Canada
Mallinckrodt Investigational Site
Temuco, Chile
Mallinckrodt Investigational Site
La Serena, Coquimbo Region, Chile
Mallinckrodt Investigational Site
Monterrey, Nuevo León, Mexico
Mallinckrodt Investigational Site
San Nicolás de los Garza, Nuevo León, Mexico
Mallinckrodt Investigational Site 307
Adana, Turkey (Türkiye)
Mallinckrodt Investigational Site 305
Ankara, Turkey (Türkiye)
Mallinckrodt Investigational Site 308
Ankara, Turkey (Türkiye)
Mallinckrodt Investigational Site 302
Antalya, Turkey (Türkiye)
Mallinckrodt Investigational Site 301
Istanbul, Turkey (Türkiye)
Mallinckrodt Investigational Site 309
Istanbul, Turkey (Türkiye)
Mallinckrodt Investigational Site 303
Izmir, Turkey (Türkiye)
Mallinckrodt Investigational Site 310
Kocaeli, Turkey (Türkiye)
Mallinckrodt Investigational Site 304
Mersin, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.